Ciba Pharmaceutical Products, Inc. v. United States

40 Cust. Ct. 307
CourtUnited States Customs Court
DecidedMay 28, 1958
DocketC. D. 1999
StatusPublished
Cited by1 cases

This text of 40 Cust. Ct. 307 (Ciba Pharmaceutical Products, Inc. v. United States) is published on Counsel Stack Legal Research, covering United States Customs Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ciba Pharmaceutical Products, Inc. v. United States, 40 Cust. Ct. 307 (cusc 1958).

Opinion

Wilson, Judge:

The merchandise at bar, invoiced as “2-Benzyl-4: 5-Imidazoline HydRochloeide,” was classified at the rate of 45 per centum ad valorem and 7 cents per pound under paragraph 28 (a) of the Tariff Act of 1930 as a coal-tar medicinal.

Plaintiff claims the merchandise should be classified under paragraph 5 of the Tariff Act of 1930 at the rate of 25 per centum ad valorem as a “medicinal preparation, not specially provided for,” or, alternatively, under paragraph 34 of the said act, as modified by the General Agreement on Tariffs and Trade, T. D. 51802, at the rate of 5 per centum ad valorem as a “drug advanced.” Plaintiff relies principally on its claim for classification under paragraph 5, supra. The product in question is known in commerce as “Priscoline hydrochloride” and will be referred to hereinafter as “Priscoline.”

The pertinent portions of the Tariff Act of 1930 herein involved provide as follows:

[Paragraph 28 (a)]:
* * * acetanilide suitable for medicinal use, * * * salol, and other medicináis; * * * all the foregoing products provided for in this paragraph, when obtained, derived, or manufactured in whole or in part from any of the products provided for in paragraph 27 or 1651; * * * 45 per centum ad valorem and 7 cents per pound.
[Paragraph 5]:
All chemical elements, all chemical salts and compounds, all medicinal preparations, and all combinations and mixtures of any of the foregoing, all the fore[309]*309going obtained naturally or artificially and not specially provided for, 25 per centum ad valorem.

Attention is here directed to the fact that paragraphs 27 and 1651 of the Tariff Act of 1930, referred to in paragraph 28, also provide for the classification of “Coal-tar products” and that toluene, a distillate of coal tar, is designated eo nomine in paragraph 1651.

There is no dispute as to the constituent parts of Priscoline, nor as to its method of manufacture, the process employed in its production being substantially as follows:

The beginning materials are benzyl cyanide and anhydrous ethylene diamine, which are reacted in the presence of catalytic quantities of carbon disulfide. In the process, ammonia splits off, leaving the 2-benzyl-4:5-imidazoline base. After this latter material is distilled in vacuum and dissolved in alcohol, it is filtered with charcoal. The base is then converted into 2-benzyl-4:5-imidazoline hydrochloride by mixing it with hydrogen chloride. In the production of Priscoline, therefore, two chemical reactions take place. First, that between the benzyl cyanide and the anhydrous ethylene diamine; and, second, between the 2-benzyl-4:5-imidazoline base and hydrogen chloride. Benzyl cyanide, one of the beginning substances, is derived from toluene, which is admitted to be a coal-tar derivative. Toluene is obtained by a fractional distillation of bituminous coal, a natural product. Ethylene diamine, the other beginning substance, is a non-coal-tar product, the ethylene being derived from a natural gas.

The testimony of plaintiff’s witness, Dr. Robert S. Miner, Jr., indicates that the constituent parts of the final product, Priscoline, consist of a phenyl radical, which is coal-tar in origin, a methylene group, an imidazoline radical, and hydrogen chloride. While the methylene group, in some instances, may be derived from non-coal-tar sources, yet, the methylene group in the imported Priscoline of necessity came from a coal-tar source, as appears from the following testimony by Dr. Miner:

Q. Well, if you say it comes from the toluene, why do you say it’s non-coal tar? — A. The benzyl cyanide, of course, is derived from other sources, as well as toluene, and the methylene group admittedly can come from the toluene. But necessarily does it? I don’t know.
Q. Well, in this reaction that he has here in which he combines benzyl cyanide and ethylene diamine, where else could that CH2 come from? — A. No other place. [R. 23.]

It appears, therefore, that the final product, Priscoline, consists of a phenyl radical, admittedly a coal-tar product; a methylene group which was derived from toluene, concededly a coal-tar substance; an imidazoline radical of non-coal-tar origin; and hydrogen chloride, which is a non-coal-tar product. On the indicated analysis, Dr. [310]*310Miner classified the Priscoline as an imidazoline derivative, principally non-coal tar from a chemical point of view (R. 28). The witness testified that the products enumerated in paragraph 28 (a), supra, are principally coal-tar products, but that they are different from Priscoline in that none of them is an imidazoline derivative. They do not contain the imidazoline ring (R. 28-30). Dr. Miner gave the percentages by weight of the constituent parts of Priscoline as follows: The phenyl radical 39.2 percent; the imidazoline ring 35.1 percent; the methylene group 7.1 percent; and the hydrogen chloride 18.6 percent. The percentage by weight, therefore, of the two coal-tar derivatives, the phenyl radical and the methylene group, is 46.3 percent.

The uncontroverted testimony of Dr. J. Cambell Howard, Jr., and Dr. Andrew G. Prandoni, two medical doctors called by the plaintiff, is, in substance, to the effect that Priscoline is a medicinal used for the treatment of “various peripheral vascular conditions that are associated with arterial vascular spasm” and is “a vasodilating compound, something that will relax the spasm and dilate the vessels” (R. 65). The witnesses further testified that histamine is also a vasodilator, used therapeutically for the same purpose as Priscoline, except that the effect produced by the administration. of histamine is of very short duration, requiring a constant dripping of the histamine into the system by injection for its effectiveness; that, unlike the imported product, histamine cannot be administered by mouth, whereas Priscoline can be and is effective for a considerable period of time. According to the doctors’ testimony, histamine, as well as other me-dicináis used as vasodilators, is an imidazoline derivative and Priscoline’s therapeutic value stems from its imidazoline radical. However, under cross-examination, the doctors admitted that there are imidazoline derivatives, used as medicináis, which are vascular constrictors, that is, they produce the opposite effect to that which results from the administration of histamine and Priscoline.

All the witnesses called by the plaintiff agreed that the substances enumerated in paragraph 28 (a), supra, are not used for the same purposes; that while none of them are used as vasodilators, they are all used in various ways for the treatment of diseases (R. 78-79).

On cross-examination, Dr. Howard agreed with the statement contained in “The Pharmacological Basis of Therapeutics,” by Goodman and Gilman, to the effect that all drugs may be divided into two categories: First, those that act upon the patient, that is, pharma-codynamic agents; and, second, those which destroy parasites, or chemotherapeutic agents. He further stated that some of the substances named in paragraph 28 (a) could be listed under both of these [311]*311Leadings and tLe balance under one or the other; that Priscoline is a pharmacodynamic agent; that antistine hydrochloride, which has the same imidazoline structure as Priscoline hydrochloride, is an antihistamine, being neither a vasodilator nor a vasoconstrictor.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sandoz Chemical Works, Inc. v. United States
47 Cust. Ct. 80 (U.S. Customs Court, 1961)

Cite This Page — Counsel Stack

Bluebook (online)
40 Cust. Ct. 307, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ciba-pharmaceutical-products-inc-v-united-states-cusc-1958.